Search

Your search keyword '"Sutton, Rosemary"' showing total 604 results

Search Constraints

Start Over You searched for: Author "Sutton, Rosemary" Remove constraint Author: "Sutton, Rosemary"
604 results on '"Sutton, Rosemary"'

Search Results

1. FDA-approved disulfiram as a novel treatment for aggressive leukemia

2. Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients

3. Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma

4. The recombinome of IKZF1 deletions in B-cell precursor ALL

7. Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions

8. Genetic characterization and therapeutic targeting of MYC‐rearranged T cell acute lymphoblastic leukaemia

9. Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma

10. Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study

11. An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL

12. Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study

14. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study

17. The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemia

18. Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma

19. Targeted treatment options for paediatric B-cell precursor acute lymphoblastic leukaemia patients with constitutional or somatic chromosome 21 alterations

20. More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling

23. Reproducible Bioinformatics Analysis Workflows for Detecting IGH Gene Fusions in B-Cell Acute Lymphoblastic Leukaemia Patients

24. P365: SEQUENTIAL BLINATUMOMAB WITH REDUCED INTENSITY CHEMOTHERAPY FOR OLDER ADULTS WITH NEWLY DIAGNOSED PH- B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA – FINAL RESULTS OF THE ALLG ALL08 STUDY

26. Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL–USP2 fusions

28. Equity Issues in High Stakes Computerized Testing.

34. Data from Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant

35. Supplemental Materials and Methods from Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant

36. Supplemental Figures and Tables from Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant

37. Supplementary Methods, Figures S1-S8, Tables S1-S7 from Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant MLL-Rearranged Acute Lymphoblastic Leukemia

38. Supplemental Figure Legends from Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant

39. Supplementary Table S5 from Quantitative Phosphotyrosine Profiling of Patient-Derived Xenografts Identifies Therapeutic Targets in Pediatric Leukemia

40. Supplementary Figure Legends 1-3 from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

41. Data from Quantitative Phosphotyrosine Profiling of Patient-Derived Xenografts Identifies Therapeutic Targets in Pediatric Leukemia

42. Supplementary Methods and References from Quantitative Phosphotyrosine Profiling of Patient-Derived Xenografts Identifies Therapeutic Targets in Pediatric Leukemia

43. Supplementary Figure 1 from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

44. Data from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

45. Supplementary Figure 3 from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

46. Supplementary Figures S1-S9 from Quantitative Phosphotyrosine Profiling of Patient-Derived Xenografts Identifies Therapeutic Targets in Pediatric Leukemia

47. Supplementary Figure 2 from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

48. Supplementary Figure Legends from Quantitative Phosphotyrosine Profiling of Patient-Derived Xenografts Identifies Therapeutic Targets in Pediatric Leukemia

49. The recombinome of IKZF1 deletions in B-ALL

50. Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia

Catalog

Books, media, physical & digital resources